Literature DB >> 27065589

Accuracy of Reverse Dot-Blot PCR in Detection of Different β-Globin Gene Mutations.

N El-Fadaly1, A Abd-Elhameed1, E Abd-Elbar1, M El-Shanshory2.   

Abstract

Prevention programs for β-thalassemia based on molecular diagnosis of heterozygous carriers and/or patients require the use of reliable mutation screening methods. The aim of this study was to compare between direct DNA sequencing, and reverse dot-blot PCR in detection of different β-globin gene mutations in Egyptian children with β-thalassemia. Forty children with β-thalassemia were subjected to mutation analysis, performed by both direct DNA sequencing and β-globin Strip Assay MED™ (based on reverse dot-blot PCR). The most frequent mutant alleles detected by reverse dot-blot PCR were; IVSI-110 G>A (31.25 %), IVS I-6 T > C (21.25 %), and IVS I-1 G>A (20 %). Relatively less frequent mutant alleles detected by reverse dot-blot PCR were "IVSII-1 G>A (5 %), IVSII-745 C>G (5 %), IVSII-848 C>A (2.5 %), IVSI-5 G>C (2.5 %), -87 C>G(2.5 %), and cd39 C>T (2.5 %)", While the genotypes of three patients (6 alleles 7.5 %) were not detected by reverse dot-blot PCR. Mutant alleles detected by direct DNA sequencing were the same as reverse dot-blot PCR method except it revealed the genotypes of 3 undetected patients (one patient was homozygous IVSI-110 G>A, and two patients were homozygous IVS I-1 G>A. Sensitivity of the reverse dot-blot PCR was 92.5 % when compared to direct DNA sequencing for detecting β-thalassemia mutations. Our results therefore suggest that, direct DNA sequencing may be preferred over reverse dot-blot PCR in critical diagnostic situations like genetic counseling for prenatal diagnosis.

Entities:  

Keywords:  DNA sequencing; Genetic mutations; β-Globin Strip Assay MED™ (reverse dot-blot PCR); β-Thalassemia

Year:  2015        PMID: 27065589      PMCID: PMC4788995          DOI: 10.1007/s12288-015-0553-y

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  18 in total

1.  Spectrum of beta-thalassemia mutations in Egypt.

Authors:  J S Waye; S Borys; B Eng; M Patterson; D H Chui; O M Badr El-Din; M K Aref; Z Afify
Journal:  Hemoglobin       Date:  1999-08       Impact factor: 0.849

2.  Molecular updating of β-thalassemia mutations in the Upper Egyptian population.

Authors:  Essam H Jiffri; Neda Bogari; Khaled H Zidan; Salwa Teama; Nasser A Elhawary
Journal:  Hemoglobin       Date:  2010       Impact factor: 0.849

Review 3.  Hemoglobin research and the origins of molecular medicine.

Authors:  Alan N Schechter
Journal:  Blood       Date:  2008-11-15       Impact factor: 22.113

4.  Molecular basis of beta-thalassemia in Alexandria.

Authors:  Aida Omar; Elham Abdel Karim; Wessam E L Gendy; Iman Marzouk; Mona Wagdy
Journal:  Egypt J Immunol       Date:  2005

Review 5.  Beta-thalassaemia.

Authors:  S L Thein
Journal:  Baillieres Clin Haematol       Date:  1998-03

Review 6.  Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination.

Authors:  C A Kattamis; A C Kattamis
Journal:  Semin Hematol       Date:  1995-10       Impact factor: 3.851

Review 7.  Molecular therapies in beta-thalassaemia.

Authors:  Lynn Quek; Swee Lay Thein
Journal:  Br J Haematol       Date:  2006-11-27       Impact factor: 6.998

8.  Prenatal diagnosis of beta-thalassemia by reverse dot-blot hybridization in southern China.

Authors:  Dongzhi Li; Can Liao; Jian Li; Yining Huang; Xingmei Xie; Jiaxue Wei; Shaoqing Wu
Journal:  Hemoglobin       Date:  2006       Impact factor: 0.849

9.  Prevention of hemoglobinopathies in Egypt.

Authors:  Amal El-Beshlawy; Ilham Youssry
Journal:  Hemoglobin       Date:  2009       Impact factor: 0.849

10.  Prevalence of hepatitis C infection among children with β-thalassaemia major in Mid Delta, Egypt: a single centre study.

Authors:  Mohamed R El-Shanshory; Ibrahim A Kabbash; Hanan H Soliman; Hala M Nagy; Said H Abdou
Journal:  Trans R Soc Trop Med Hyg       Date:  2013-01-22       Impact factor: 2.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.